Similar articles

• The role of alpha-synuclein in Parkinson's disease: insights from animal models.

  Maries E, Dass B, Collier TJ, Kordower JH, Steece-Collier K. Maries E, et al. Nat Rev Neurosci. 2003 Sep;4(9):727-38. doi: 10.1038/nrn1199. Nat Rev Neurosci. 2003. PMID: 12951565 Review. No abstract available.
• A Drosophila model of Parkinson's disease.

  Feany MB, Bender WW. Feany MB, et al. Nature. 2000 Mar 23;404(6776):394-8. doi: 10.1038/35006074. Nature. 2000. PMID: 10746727
• Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease.

  Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. Auluck PK, et al. Science. 2002 Feb 1;295(5556):865-8. doi: 10.1126/science.1067389. Epub 2001 Dec 20. Science. 2002. PMID: 11823645
• Pharmacological prevention of Parkinson disease in Drosophila.

  Auluck PK, Bonini NM. Auluck PK, et al. Nat Med. 2002 Nov;8(11):1185-6. doi: 10.1038/nm1102-1185. Nat Med. 2002. PMID: 12411925 No abstract available.
• Experimental models of Parkinson's disease.

  Beal MF. Beal MF. Nat Rev Neurosci. 2001 May;2(5):325-34. doi: 10.1038/35072550. Nat Rev Neurosci. 2001. PMID: 11331916 Review.